VBI Vaccines Inc. (TSE:VBV) shares shot up 0.2% during trading on Thursday after an insider bought additional shares in the company. The stock traded as high as C$6.25 and last traded at C$6.16. 5,050 shares traded hands during mid-day trading, an increase of 11% from the average session volume of 4,538 shares. The stock had previously closed at C$6.15.

Specifically, Director Jeffrey Royston Baxter acquired 15,000 shares of the business’s stock in a transaction dated Tuesday, November 28th. The stock was bought at an average price of C$4.75 per share, with a total value of C$71,250.00.

TRADEMARK VIOLATION NOTICE: “VBI Vaccines (VBV) Shares Up 0.2% Following Insider Buying Activity” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/12/02/vbi-vaccines-vbv-shares-up-0-2-following-insider-buying-activity.html.

VBI Vaccines Company Profile

VBI Vaccines Inc, a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology that enables the thermostabilization of vaccines through a proprietary formulation and freeze-drying process.

Receive News & Stock Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related stocks with our FREE daily email newsletter.